Current and emerging treatments for the management of myasthenia gravis
Open Access
- 1 July 2011
- journal article
- Published by Taylor & Francis Ltd in Therapeutics and Clinical Risk Management
- Vol. 7, 313-323
- https://doi.org/10.2147/tcrm.s14015
Abstract
Peer reviewed article authored by (Sathasivam S). Read article or submit your manuscript for publishing.Keywords
This publication has 101 references indexed in Scilit:
- IV immunoglobulin in patients with myasthenia gravisNeurology, 2007
- Cyclosporine in the treatment of myasthenia gravisActa Neurologica Scandinavica, 2005
- Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravisCurrent Medical Research and Opinion, 2004
- Dendritic cells exposedin vitroto TGF-β1 ameliorate experimental autoimmune myasthenia gravisClinical and Experimental Immunology, 2002
- Oral administration of acetylcholine receptor: Effects on experimental myasthenia gravisAnnals of Neurology, 1994
- Suppression of Experimental Autoimmune Myasthenia Gravis by Epitope-Specific Neonatal Tolerance to Synthetic Region α146-162 of Acetylcholine ReceptorClinical Immunology and Immunopathology, 1993
- Experience with intravenous immunoglobulin in myasthenia gravisClinical Immunology and Immunopathology, 1989
- Preliminary Results of a Double-Blind, Randomized, Placebo-Controlled Trial of Cyclosporine in Myasthenia GravisThe New England Journal of Medicine, 1987
- Plasma exchange in myasthenia gravis: effect on anti-AChR antibodies and other autoantibodiesActa Neurologica Scandinavica, 1986
- INTRODUCTIONActa Neurologica Scandinavica, 1966